InsidersTradesSigma
Hansa Biopharma AB Stock: price and management transactions · Finland · FIN-FSA
Follow the Hansa Biopharma AB share price and the full management transaction log of the company, a publicly traded company based in Finland. Shares are listed on FI FI, under the supervision of FIN-FSA. Operating in the Health Care sector, Hansa Biopharma AB has recorded 6 public disclosures. Market capitalisation: €3.1bn. The latest transaction was filed on 11 March 2026 (Purchase). Among the most active insiders: RENÉE AGUIAR LUCANDER. Every trade is accessible without an account.
6
Insider Decl.
0
Thresholds
€2m
5 ops.
Buy Volume
€19,037
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Hansa Biopharma AB Strong Buy (bullish), based on 7 analysts. Average price target: SEK 75.71.
39Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 11 March 2026
Declarations6 total
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
1,688 shares@ €2.77810.0002% mcap100.0% of flowAktieFI:A003W932-1
Ideal exit: 6 Dec 2026 (T+270)
1,652,500 shares@ €0.9740.056% mcap92.9% of flowTeckningsoptionFI:A003R120-1
Ideal exit: 23 Apr 2026 (T+270)
50,000 shares@ €2.45870.0043% mcap7.1% of flowAktieFI:A003R122-1
Ideal exit: 24 Apr 2026 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
8,056 shares@ €2.36310.0007% mcap100.0% of flowAktieFI:A003R005-1
15,050 shares0AktieFI:A003R004-1
Ideal exit: 18 Apr 2026 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
300 shares@ SEK 185.70100.0% of flowAktieFI:A001P621-2
Ideal exit: 16 Oct 2021 (T+270)
6 of 6 declarations